Suppliers / Lonza

Lonza

Switzerland 2 duplicate records merged Updated 9 July 2026

Lonza is an API manufacturer based in Switzerland. It holds 5 active US drug master files and 4 valid CEPs across a filed portfolio of 9 molecules. Its filings concentrate with ARCSA (EC), MINSA (CR) and INVIMA (CO). Its GMP standing is certified by EMA, MHRA (UK) and HSA (SG), among 7 authorities. Its most recent recorded inspection, by US FDA, closed on 6 February 2026 as VAI.

5
active US DMFs
4
valid CEPs
12
registered plants 5 with an FDA FEI number
21
filings across 4 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
5 of 5 confirmed
Inspections
6 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 6 February 2026 VAI US FDA
  • 7 March 2024 VAI US FDA
  • 21 July 2023 VAI US FDA
  • 27 June 2023 VAI US FDA
  • 28 March 2023 VAI US FDA
  • 4 November 2022 NAI US FDA
  • 13 October 2022 VAI US FDA
  • 5 August 2022 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Geleen, United Arab Emirates Not on file
Braine-Lalleud, Belgium Not on file
Braine-L'Alleud, Belgium Not on file
Switzerland, Switzerland 3016502617
Switzerland, Switzerland 3012793444
Stein Ag, Switzerland Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Nicotinamide EDQM, US FDA 2
Nicotinic Acid EDQM 2
Desmopressin EDQM 1
Dexmethylphenidate US FDA 1
Fluvoxamine US FDA 1
Macitentan SFDA (Saudi Arabia) 1
Pomalidomide SFDA (Saudi Arabia) 1
Sirolimus US FDA 1
Voclosporin US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
ARCSA (EC) 11 None
MINSA (CR) 4 None
INVIMA (CO) 4 None
EEC_EAEU 2 None
EMA None 11
MHRA (UK) None 7
HSA (SG) None 2
MFDS (Korea) None 2
US FDA None 2
ANVISA (Brazil) None 1
AEMPS (ES) None 1

Comparing suppliers?

Choose your molecules and target markets. Lonza comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 2 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 6 February 2026.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates